M13 Phage

M13 Phage Gene Editing

1. Research Background

M13 phage is a filamentous phage with high research value and wide application in biotechnology. Featuring a compact single-stranded DNA (ssDNA) genome, a unique non-lytic life cycle that does not lyse host cells, and excellent modifiability, M13 has become a core chassis for phage display technology, nanomaterial synthesis, and gut microbiome editing. Precise and efficient gene editing technologies provide key tools for developing novel antibody screening platforms, constructing engineered nanoscaffolds, and creating precision medical vectors.

Against this background, GeneRulor offers customized genome engineering services for M13 phage. Using the CRISPR/Cas9-assisted selection system or classical reverse genetics techniques, we can achieve scarless knockout, point mutation, large-fragment insertion, and fusion expression of foreign peptides/proteins at target loci (e.g., gIII, gVIII) in the M13 genome. We are committed to providing professional and reliable M13 phage gene editing solutions for global research and industrial clients.

2. Phage Characteristics and Biological Background

(1) Structure and Properties

M13 belongs to the family Inoviridae (filamentous phages) and has an elongated filamentous morphology, with a diameter of approximately 6 nm and a length of 880–900 nm. As a non-lytic bacteriophage, it releases progeny virions through secretion without causing lysis of host Escherichia coli cells, thus forming characteristic "cloudy" plaques.

(2) Genomic Features

It possesses a circular single-stranded DNA (ssDNA) genome of approximately 6.4 kb, encoding 11 genes (gI–gXI).

(3) Application Value

As the cornerstone of phage display technology, M13 is widely used in the screening of antibody and peptide libraries. In addition, its highly ordered surface protein arrangement (e.g., pVIII) makes it an ideal scaffold for the research of nanowires, biosensors, and drug delivery systems.

Figure 1. M13 phage

3. Reported Editing Strategies in Literature

Given the single-stranded DNA (ssDNA) replication characteristics of M13 phage and the presence of double-stranded DNA intermediates (RF form) in host cells, the mainstream editing strategies include:

3.1 CRISPR/Cas9-Assisted Selection System (High-Efficiency Strategy)

(1) Principle: The Cas9 protein is used to specifically cleave wild-type phage DNA, acting as a negative selection pressure.

(2) Advantage: Only mutant phages with the expected edits (that have escaped cleavage) are retained, which greatly improves the extremely low screening efficiency of traditional recombination methods.

3.2 Reverse Genetics / Molecular Cloning Method

The double-stranded replicative form (RF) DNA of M13 is directly used as a vector for restriction enzyme cloning or Gibson assembly in vitro, followed by transformation into Escherichia coli to "rescue" the phage.

3.3 Helper Phage System

Helper phages such as M13KO7 provide packaging proteins for phagemid libraries, enabling large-scale display of specific proteins.

3.4 Transformation Efficiency Optimization

By optimizing the electroporation parameters of recipient Escherichia coli (e.g., DH5α-F'), the efficient introduction of large recombinant genomes is ensured.

4. Core Application Areas

(1) Phage Display Library Construction: Insert foreign peptide sequences at the N-terminus of the gIII or gVIII gene for high-throughput drug screening.

(2) Nanomaterial Modification: Modify the major coat protein pVIII through site-directed mutagenesis to endow it with specific metal-binding or semiconductor assembly capabilities.

(3) Precision Microbiome Editing: Use engineered M13 as a vector to deliver the CRISPR/Cas system to specific Escherichia coli, achieving strain-specific clearance or gene deletion.

(4) Novel Vaccine Development: Fusion of pathogen epitopes on the phage surface to construct particulate vaccines with strong immunogenicity.

5. Project Workflow & Validation

We provide one-stop services from design to delivery to ensure the accuracy of editing results:

(1) Strategy Design & Vector Construction: Design fusion expression or mutation strategies for target proteins (e.g., pIII).

(2) Recombinant DNA Transformation & Packaging: Introduce the edited phage genome or plasmid into host bacteria for packaging.

(3) Enrichment & Screening of Mutants: Screen positive phage clones using CRISPR selection pressure or resistance markers.

(4) Multilevel Validation: Ensure successful editing through single-plaque PCR identification, Sanger sequencing, and Western Blot.

Figure 2. Schematic Diagram of Project Workflow

6. Introduction to Gene Editing Projects

6.1 Core Services

(1) Gene Fusion / Insertion: Scarlessly insert foreign sequences at specific sites of pIII or pVIII proteins while maintaining phage infectivity.

(2) Site-Directed Mutagenesis / Modification: Precise substitution of amino acids in key proteins to alter their charge properties or binding affinity.

(3) Functional Element Integration: Integration of promoters or reporter genes into intergenic regions of the genome.

(4) Large-Fragment Deletion: Removal of auxiliary regions to construct novel minimal chassis phages with streamlined genomes.

6.2 Technical Advantages

(1) High Success Rate: Our independently developed CRISPR/Cas9 negative selection platform ensures the efficient detection of mutant strains.

(2) Customized Design: Provide optimal fusion site selection strategies according to client needs (e.g., nanomaterial applications or antibody screening).

(3) Scarless Editing: No unnecessary resistance markers are introduced, which is fully compliant with subsequent biosafety evaluations.

7. Case Studies

We have successfully provided services to numerous top universities, research institutes, and biotechnology companies at home and abroad. Selected examples are as follows:

Case: M13 Phage-Mediated Plasmid Delivery into Host Bacteria

Project Description: Package and deliver plasmids into host bacteria using M13 phage.

Figure 3. Delivery of kanamycin-resistant plasmids to host bacteria by replication-defective M13 phages

8. References

[1] Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science.

[2] Lam, K. N., et al. (2021). Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Reports.

[3] Turnbaugh, P. J., et al. (2022). Engineering the gut microbiome with bacteriophage. Nature Reviews Microbiology.

[4] Wang, R., et al. (2023). M13 Phage Genome Sequencing: From Display Libraries to Data Analysis. Journal of Biotechnology.